| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | A27L |
| Uniprot No | Q89694 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-194aa |
| 氨基酸序列 | MEKEIQRLRDRIMDLDRQLNECKRNGNGTSSEEVNRLKTRISDLKQSLEI CLKDKSELYSAYKTELGRVREQISNLQESLRRERESDKTDSYYRRELTRE RNKIVELEKELNKCFDVNHVKYIDEINSKKNRISDLERQLTACKSNGCGN GDMDQYKREIESLKRELTKCRRGSNGSHSDCEYYDEEARDCVKS |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于A27L重组蛋白的3篇文献示例(内容基于公开研究归纳，非真实文献)：
1. **文献名称**：*Structural characterization of the vaccinia virus A27L protein and its role in viral entry*
**作者**：Smith J, Moss B
**摘要**：解析痘苗病毒A27L蛋白的晶体结构，揭示其通过结合细胞表面硫酸乙酰肝素介导病毒吸附宿主细胞的过程，并证实重组A27L蛋白可诱导中和抗体。
2. **文献名称**：*A27L recombinant protein as a subunit vaccine candidate against smallpox*
**作者**：Benhnia MR, et al.
**摘要**：评估重组A27L蛋白的免疫原性，证明其在小鼠模型中能激发Th1型免疫应答，并提供针对痘病毒攻击的部分保护作用。
3. **文献名称**：*Functional analysis of A27L in vaccinia virus morphogenesis*
**作者**：Fogg C, Niles EG
**摘要**：通过基因敲除实验发现A27L蛋白对病毒粒子组装至关重要，重组表达A27L可恢复缺陷型病毒的感染性，揭示其在病毒包膜形成中的结构功能。
(注：以上为模拟文献，实际文献需通过PubMed/Google Scholar检索关键词 "A27L protein recombinant" 或结合具体病毒名称查询。)
The A27L recombinant protein is derived from the A27L gene of vaccinia virus, a member of the poxvirus family, closely related to variola virus (smallpox). As a key structural protein, A27L plays a critical role in viral attachment, entry, and cell-to-cell spread. It is a 14-16 kDa envelope glycoprotein that interacts with host cell surface glycosaminoglycans (GAGs), facilitating viral binding and membrane fusion. Additionally, A27L contributes to the formation of extracellular enveloped virions (EEVs), critical for systemic viral dissemination.
Recombinant A27L protein is produced via genetic engineering, often expressed in bacterial or mammalian systems, enabling scalable purification for research and therapeutic applications. Its immunogenic properties have made it a focus in vaccine development, particularly for cross-protective vaccines against poxviruses. Studies show that A27L-specific antibodies can neutralize viral infectivity, highlighting its potential as a target for antibody-based therapies or subunit vaccines.
Research on A27L also extends to structural biology, elucidating its interaction with host receptors and other viral proteins (e.g., L1 and H3). This informs antiviral drug design and mechanisms of immune evasion. Furthermore, A27L’s role in viral pathogenesis and immune modulation is explored to understand poxvirus-host dynamics, aiding the development of oncolytic viruses or vaccine vectors.
As smallpox remains a biosecurity concern, A27L recombinant protein serves as a vital tool for diagnostics, vaccine evaluation, and preparedness against poxvirus threats. Its study bridges virology, immunology, and biotech, underscoring its relevance in public health and biodefense strategies.
×
